scholarly journals Adequacy of Olmesartan monotherapy versus cotherapy in patients with essential hypertension

2020 ◽  
Vol 11 (2) ◽  
pp. 1649-1654
Author(s):  
Feryal Hashim Rada
Keyword(s):  
Blood Pressure ◽  
Essential Hypertension ◽  
Insulin Sensitivity ◽  
Clinical Laboratory ◽  
Olmesartan Medoxomil ◽  
Blood Levels ◽  
Sensitivity Index ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Treatment Of Hypertension

Olmesartan is a class of an angiotensin II receptor blocker drugs used for the treatment of hypertension. The aim of this crossover clinical study is to evaluate the safety and effectiveness of Olmesartan monotherapy compared to Olmesartan plus amlodipine co-therapy in patients with essential hypertension. An entire of eighty-three patients (45 males, 38 females) their age ranging  (45-55 ) years with essential hypertension enrolled from Al Yarmouk hospital /Iraq for this study. After reaching the point of inclusion criteria, they treated with Olmesartan medoxomil 20 mg daily for a period of two months, then after two weeks of wash off, they treated with Olmesartan 20 mg daily plus amlodipine 10 mg daily for another two months. Blood pressure (systolic and diastolic) and clinical laboratory tests that include fasting blood levels of glucose, insulin, lipid profile, adiponectin, leptin, cystatin c and creatinine were obtained and studied at baseline (prior treatment), after two months of Olmesartan monotherapy and after two months of Olmesartan co-therapy.The statistical analyses of the data in patients using Olmesartan co-therapy versus Olmesartan monotherapy showed more effectiveness in decreasing blood pressure, better in reducing the blood levels of glucose, insulin, total cholesterol, triglyceride, and leptin, superior in elevating the values of insulin sensitivity index and in elevating the blood levels of adiponectin. Concisely, the addition of amlodipine to Olmesartan treatment ameliorated insulin sensitivity and adiponectin level and attenuated the leptin level.

Landscape of Combination Therapy – Which Way Forward? Proceedings of the Satellite Symposium Held at the ESH European Meeting on Hypertension and Cardiovascular Protection, 27 April 2012, London

2012 ◽  
Vol 8 (3) ◽  
pp. 192
Author(s):  
Patricia Fonseca ◽  
Anna F Dominiczak ◽  
Stephen Harrap ◽  
◽  
◽  
...  
Keyword(s):  
Blood Pressure ◽  
High Risk ◽  
Combination Therapy ◽  
Enzyme Inhibitor ◽  
Synergistic Effects ◽  
Term Treatment ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Patients ◽  
Long Term Treatment

Early combination therapy is more effective for hypertension control in high-risk patients than monotherapy, and current guidelines recommend the use of either an angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) for first-line therapy in patients younger than 55 years. Recent evidence shows that ACEIs reduce mortality, whereas ARBs show no apparent benefit despite their blood pressure lowering action. However, it is important to consider which blood pressure parameters should be targeted given that different drugs have distinct effects on key parameters. Remarkably, a high percentage of hypertensive patients whose treatment has brought these parameters within target ranges still remain at high risk of cardiovascular disease due to additional risk factors. Combination therapy with synergistic effects on blood pressure and metabolic control should thus be considered for the long-term treatment of hypertensive patients with co-morbid conditions.

scholarly journals Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1–7)

2011 ◽  
Vol 5 (6) ◽  
pp. 297-304 ◽  
Author(s):  
Michiya Igase ◽  
Hiroshi Yokoyama ◽  
Carlos M. Ferrario
Keyword(s):  
Blood Pressure ◽  
Angiotensin Ii ◽  
Structural Changes ◽  
Weight Ratio ◽  
Critical Factor ◽  
Vehicle Group ◽  
Glomerular Sclerosis ◽  
Angiotensin Ii Receptor Blocker ◽  
Angiotensin Ii Receptor ◽  
Hypertensive Nephropathy

Background: Controversy exists as to whether angiotensin (1–7) (Ang (1–7)) acts as a protective hormone against renal injury. Methods: We compared the degree of improvement of hypertensive nephropathy following 8 weeks’ treatment with either the angiotensin II receptor type 1 antagonist olmesartan medoxomil or the cardioselective beta blocker atenolol in 8-week-old spontaneously hypertensive rats (SHRs). Results: Both treatment regimens reduced mean blood pressure in a similar fashion, while bradycardia was present only in atenolol-treated SHRs. The heart weight:body weight ratio fell more in SHRs medicated with olmesartan versus those receiving atenolol. These changes were associated with increases in plasma Ang II in SHRs given the angiotensin II receptor blocker. At the end of treatment, plasma Ang (1–7) was higher in the olmesartan than atenolol or vehicle groups. The glomerular sclerosis (GS) index was lowered by olmesartan and atenolol compared with the vehicle group. While both olmesartan and atenolol attenuated renal perivascular collagen deposition (PVCD), the greatest effect was observed in SHRs receiving olmesartan. Elevations in plasma Ang (1–7) correlated negatively with reductions in GS or PVCD index, respectively. Conclusions: While control of blood pressure remains a critical factor in the prevention of hypertensive nephropathy, Ang (1–7) may play a substantial role in preventing the structural changes in glomerulus through its effect on regulations of blood pressure and renal function.

Sign in / Sign up

Export Citation Format

Share Document